Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: terbinafine Clear all
Not listed Phase 3 Interventional

TDT 067 Onychomycosis Study

NCT01145807
View directory record Official record
Conditions
Onychomycosis
Interventions
TDT067, Placebo, Transfersome
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Albequerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 19, 2026, 4:24 AM EDT
Not listed Phase 2 Interventional

To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

NCT05135910
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
Hallux Terbinafine Subungual Gel
Drug
Lead sponsor
Hallux, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Mesa, Arizona • Parker, Colorado • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis

NCT00691184
View directory record Official record
Conditions
Onychomycosis/Onycholysis and Tinea Pedis
Interventions
Placebo, Terbinafine Hydrochloride, Terbinafine
Drug
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 3 Interventional

Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

NCT00117754
View directory record Official record
Conditions
Tinea Capitis
Interventions
Terbinafine hydrochloride
Drug
Lead sponsor
Novartis
Industry
Eligibility
4 Years to 12 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2007 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

NCT00002394
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Terbinafine hydrochloride
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Fort Lauderdale, Florida • Fort Myers, Florida • Tamarac, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions

NCT00602342
View directory record Official record
Conditions
Onychomycosis
Interventions
Terbinafine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 19, 2026, 4:24 AM EDT
Withdrawn Early Phase 1 Interventional

Terbinafine Treatment of Axial Spondyloarthropathy

NCT05119712
View directory record Official record
Conditions
Ankylosing Spondylitis, Axial Spondyloarthritis, Psoriatic Spondylitis, Spondylitis Secondary to Inflammatory Bowel Disease, Axial Spondyloarthopathy
Interventions
Terbinafine Tablets, Laboratory Testing
Drug · Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 2 Interventional

Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail

NCT01400594
View directory record Official record
Conditions
Onychomycosis
Interventions
HTU-520 Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® 250 mg

NCT00648713
View directory record Official record
Conditions
Healthy
Interventions
Terbinafine Hydrochloride Tablets 250 mg, Lamisil® Tablets 250 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 2 Interventional

Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail

NCT01484145
View directory record Official record
Conditions
Onychomycosis
Interventions
Terbinafine HCl
Drug
Lead sponsor
Nitric BioTherapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 3 Interventional

Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

NCT00117767
View directory record Official record
Conditions
Tinea Capitis
Interventions
Terbinafine hydrochloride (HCl), Griseofulvin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
4 Years to 12 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Terbinafine HCl 250 mg Tablet Under Fasting Conditions

NCT00833586
View directory record Official record
Conditions
Healthy
Interventions
Terbinafine HCl 250mg tablets, Lamisil® 250 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Terbinafine Tablets Under Fed Conditions

NCT00602251
View directory record Official record
Conditions
Onychomycosis
Interventions
Terbinafine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis

NCT01080079
View directory record Official record
Conditions
Onychomycosis
Interventions
Terbinafine Hydrochloride, Purified Water
Drug · Other
Lead sponsor
Nitric BioTherapeutics, Inc
Industry
Eligibility
18 Years to 69 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Birmingham, Alabama • Sanford, Florida • Snellville, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 3 Interventional

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

NCT02859519
View directory record Official record
Conditions
Distal Subungual Onychomycosis
Interventions
MOB015B, MOB015B Vehicle
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
12 Years to 75 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Multiple Locations, California • Multiple Locations, Florida • Multiple Locations, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg

NCT00647647
View directory record Official record
Conditions
Healthy
Interventions
Terbinafine Hydrochloride Tablets 250 mg, Lamisil® Tablets 250 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 2 Interventional

Topical Gel Anti-Fungal Agent for Tinea Unguium

NCT00253305
View directory record Official record
Conditions
Onychomycosis
Interventions
Organogel of naftifine, 2%, Organogel of terbinafine, 2%, Organogel of naftifine, 6%, Organogel of terbinafine, 6%
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
Birmingham, Alabama • Tucson, Arizona • Miami Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 19, 2026, 4:24 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine

NCT05667246
View directory record Official record
Conditions
Terbinafine Adverse Reaction
Interventions
Caffeinated Coffee, Decaffeinated Coffee
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443820
View directory record Official record
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Novato, California • Northglenn, Colorado • Melbourne, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 2 Interventional

Three-Arm Trial of Novel Treatment for Tinea Pedis

NCT03135912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride
Drug
Lead sponsor
South End Skin Care
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 19, 2026, 4:24 AM EDT
Not listed Phase 3 Interventional

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

NCT05279846
View directory record Official record
Conditions
Onychomycosis
Interventions
MOB015B, Vehicle (Placebo Comparator)
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
12 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Encinitas, California • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 19, 2026, 4:24 AM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis

NCT03094468
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
P-3058 (terbinafine hydrochloride 10%), Vehicle of P-3058
Drug
Lead sponsor
Polichem S.A.
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
North Hollywood, California • Oceanside, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Iontophoretic Application of Terbinafine Gel to the Large Toe Nail

NCT00768768
View directory record Official record
Conditions
Onychomycosis
Interventions
Electrokinetic Transungual System (ETS) - Terbinafine Gel, ETS-Terbinafine Gel
Other
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443898
View directory record Official record
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 19, 2026, 4:24 AM EDT